These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 35146532)

  • 1. Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
    Gottlieb AB; Deodhar A; Mcinnes IB; Baraliakos X; Reich K; Schreiber S; Bao W; Marfo K; Richards HB; Pricop L; Shete A; Trivedi V; Keefe D; Papavassilis CC; Jagiello P; Papanastasiou P; Mease PJ; Lebwohl M
    Acta Derm Venereol; 2022 Apr; 102():adv00698. PubMed ID: 35146532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
    Deodhar A; Mease PJ; McInnes IB; Baraliakos X; Reich K; Blauvelt A; Leonardi C; Porter B; Das Gupta A; Widmer A; Pricop L; Fox T
    Arthritis Res Ther; 2019 May; 21(1):111. PubMed ID: 31046809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis.
    Elewski BE; Baddley JW; Deodhar AA; Magrey M; Rich PA; Soriano ER; Soung J; Bao W; Keininger D; Marfo K; Patekar M; Sharma A; Shete A; Lebwohl MG
    JAMA Dermatol; 2021 Jan; 157(1):43-51. PubMed ID: 33001147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up.
    Lebwohl M; Deodhar A; Griffiths CEM; Menter MA; Poddubnyy D; Bao W; Jehl V; Marfo K; Primatesta P; Shete A; Trivedi V; Mease PJ
    Br J Dermatol; 2021 Nov; 185(5):935-944. PubMed ID: 33829482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study.
    Kiltz U; Sfikakis PP; Gaffney K; Sator PG; von Kiedrowski R; Bounas A; Gullick N; Conrad C; Rigopoulos D; Lespessailles E; Romanelli M; Ghislain PD; Brandt-Jürgens J; Rashkov R; Aassi M; Orsenigo R; Perella C; Pournara E; Gathmann S; Jagiello P; Veit J; Augustin M
    Adv Ther; 2020 Jun; 37(6):2865-2883. PubMed ID: 32378070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secukinumab for children and adolescents with enthesitis-related arthritis and psoriatic arthritis:
    Bagri NK; King H; Ramanan AV
    Expert Rev Clin Immunol; 2024 May; 20(5):435-440. PubMed ID: 38186357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.
    Schreiber S; Colombel JF; Feagan BG; Reich K; Deodhar AA; McInnes IB; Porter B; Das Gupta A; Pricop L; Fox T
    Ann Rheum Dis; 2019 Apr; 78(4):473-479. PubMed ID: 30674475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.
    Deodhar A; Blauvelt A; Lebwohl M; Feely M; Kronbergs A; Eberhart N; Zhu D; Inman E; Grace E; Holzkaemper T; Rahman P; Marzo-Ortega H; Papp KA; Merola JF; Gottlieb AB; Schwartzman S
    Arthritis Res Ther; 2024 Feb; 26(1):49. PubMed ID: 38347650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
    Burmester GR; Stigler J; Rubbert-Roth A; Tanaka Y; Azevedo VF; Coombs D; Lagunes I; Lippe R; Wung P; Gensler LS
    Rheumatol Ther; 2024 Jun; 11(3):737-753. PubMed ID: 38683479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment-emergent Candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with ixekizumab: an integrated safety analysis of 25 clinical studies.
    Schwartzman S; Puig L; Cohen AD; Khattri S; Jossart C; Diaz C; Garrelts A; Ngantcha M; Eberhart N; Eleftheriadi A; Tangsirisap N; Schuster C; Gottlieb AB
    Expert Opin Drug Saf; 2024 Oct; 23(10):1347-1357. PubMed ID: 39234767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.
    Burmester GR; Panaccione R; Gordon KB; McIlraith MJ; Lacerda AP
    Ann Rheum Dis; 2013 Apr; 72(4):517-24. PubMed ID: 22562972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secukinumab for the treatment of psoriatic arthritis.
    Baronaite Hansen R; Kavanaugh A
    Expert Rev Clin Immunol; 2016 Oct; 12(10):1027-36. PubMed ID: 27550397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease.
    Reich K; Warren RB; Coates LC; Di Comite G
    J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1161-1173. PubMed ID: 31785165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secukinumab: first global approval.
    Sanford M; McKeage K
    Drugs; 2015 Feb; 75(3):329-38. PubMed ID: 25648267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis.
    van de Kerkhof PCM
    Br J Dermatol; 2021 Nov; 185(5):879. PubMed ID: 34402525
    [No Abstract]   [Full Text] [Related]  

  • 16. Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis.
    Conesa-Nicolás E; García-Lagunar MH; Núñez-Bracamonte S; García-Simón MS; Mira-Sirvent MC
    Farm Hosp; 2020 Dec; 45(1):16-21. PubMed ID: 33443473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety.
    Kolbinger F; Di Padova F; Deodhar A; Hawkes JE; Huppertz C; Kuiper T; McInnes IB; Ritchlin CT; Rosmarin D; Schett G; Carballido JM; Häusermann P; Calonder C; Vogel B; Rondeau JM; Bruin G
    Pharmacol Ther; 2022 Jan; 229():107925. PubMed ID: 34171337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secukinumab as a potential trigger of inflammatory bowel disease in ankylosing spondylitis or psoriatic arthritis patients.
    Onac IA; Clarke BD; Tacu C; Lloyd M; Hajela V; Batty T; Thoroughgood J; Smith S; Irvine H; Hill D; Baxter G; Horwood N; Mahendrakar S; Rajak R; Griffith S; Kiely PDW; Galloway J
    Rheumatology (Oxford); 2021 Nov; 60(11):5233-5238. PubMed ID: 33677579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of secukinumab in psoriasis treatment.
    Berg SH; Balogh EA; Ghamrawi RI; Feldman SR
    Immunotherapy; 2021 Feb; 13(3):201-216. PubMed ID: 33203276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating to Target(s) With Interleukin-17 Inhibitors.
    Lynde CW; Beecker J; Dutz J; Flanagan C; Guenther LC; Gulliver W; Papp K; Rahman P; Sholter D; Searles GE
    J Cutan Med Surg; 2019; 23(2_suppl):3S-34S. PubMed ID: 30742778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.